



Precision meets flexibility in cardiac PET MPI

With a 109-minute half-life^{1,2}, Flyrcado delivers superior image quality over SPECT for greater diagnostic certainty^{1,3} in more patients and flexible workflows^{2,4}

Save time with a shorter overall protocol than SPECT^{1,2}



Versatile protocols that work across patient types and for exercise stress testing^{1,2}

Re-image when needed, during the same appointment without additional dosing or radiation exposure*^{1,2}

Exercise stress capability to assess clinical function¹

The first new cardiac PET radiotracer in 25 years

*Allows for repeat imaging (static imaging, not dynamic) within 25 minutes from injection in the event of technical difficulties (e.g., patient motion), without additional dosing or radiation exposure.



The information and materials presented are specific to the GE HealthCare products detailed and is not intended nor implied to be relevant to products not manufactured by GE HealthCare. This information and material is also not a substitute for professional medical advice, diagnosis or treatment. Please utilize your own expertise and judgment while engaged in the practice of medicine. GE HealthCare does not recommend the use of its products outside the package labeling.

Please read the Full Prescribing Information: <https://www.gehealthcare.com/flyrcado-pi>

Flyrcado Exercise Stress Protocol





Image adapted from: 1. Bourque et al. Assessing myocardial aperefusion in suspected coronary artery disease: rationale and design of the second phase 3, open-label multi-center study of flurpiridaz (F-18) injection for positron emission tomography (PET) imaging. *J Nucl Card.* 2021; 28 (3);1105–16. 2. Maddahi J, Agostini D, Bateman TM, et al. Flurpiridaz F-18 PET Myocardial Perfusion Imaging in Patients With Suspected Coronary Artery Disease. *J Am Coll Cardiol.* 2023;82(16):1598-1610.



What can a 109-minute half-life do for your imaging workflows?



Scan the QR code to learn more about **Flyrcado**



Scan the QR code to view the full **Prescribing Information**

Flyrcado Support Line: 800 729 0701

Medical Affairs: 800 654 0118
(option 2, then option 3) or
medical.affairs@gehealthcare.com

Customer Service: 800 292 8514

gehealthcare.com

IMPORTANT SAFETY INFORMATION ABOUT FLYRCADO

Indications and Usage

FLYRCADO is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction.

Contraindications

None

Warnings and Precautions

Risk associated with exercise or pharmacologic stress: Patients evaluated with exercise or pharmacologic stress may experience serious adverse reactions such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction, stroke, and seizure. Perform stress testing in the setting where cardiac resuscitation equipment and trained staff are readily available. When pharmacologic stress is selected as an alternative to exercise, perform the procedure in accordance with the pharmacologic stress agent's prescribing information.

Radiation risks

FLYRCADO contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to minimize radiation exposure to patients and health care providers. Advise patients to hydrate before and after administration and to void.

Adverse Reactions

Most common adverse reactions occurring during FLYRCADO PET MPI under rest and stress (pharmacologic or exercise) (incidence ≥ 2%) are dyspnea, headache, angina pectoris, chest pain, fatigue, ST segment changes, flushing, nausea, abdominal pain, dizziness, and arrhythmia.

To report SUSPECTED ADVERSE REACTIONS, contact GE HealthCare at 800-654-0118 (option 2 then option 1) or by email at GPV.drugsafety@gehealthcare.com or FDA at 800-FDA-1088 or www.fda.gov/medwatch

References

1. Flyrcado (flurpiridaz F 18 injection). Full Prescribing Information. Marlborough, MA: GE HealthCare.
2. Patel KK, Singh A, Bateman TM. The potential of F-18 flurpiridaz PET/CT myocardial perfusion imaging for precision imaging. *Curr Cardiol Rep.* 2022;24(8):987-994.
3. Maddahi J, Agostini D, Bateman TM, et al. Flurpiridaz F-18 PET Myocardial perfusion imaging in patients with suspected coronary artery disease. *J Am Coll Cardiol.* 2023;82(16):1598-1610.
4. Driessen RS, Raijmakers PG, Stuijzfand WJ, Knaapen P. Myocardial perfusion imaging with PET. *Int J Cardiovasc Imaging.* 2017;33(7):1021-1031.

© 2025 GE HealthCare

Flyrcado is a trademark of GE HealthCare.

GE is a trademark of General Electric Company used under trademark license.

August 2025 | JB12198US